Cargando…
Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?
Metastatic melanoma remains a fatal disease to many worldwide, even after the breakthrough introduction of targeted therapies such as BRAF inhibitors and immune checkpoint blockade therapies such as CTLA-4 and PD-1 inhibitors. With advances in our understanding of this disease, as well as the increa...
Autores principales: | Tan, Lih Yin, Martini, Carmela, Fridlender, Zvi G, Bonder, Claudine S, Brown, Michael P, Ebert, Lisa M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382436/ https://www.ncbi.nlm.nih.gov/pubmed/28435677 http://dx.doi.org/10.1038/cti.2017.7 |
Ejemplares similares
-
CD36 promotes vasculogenic mimicry in melanoma by mediating adhesion to the extracellular matrix
por: Martini, Carmela, et al.
Publicado: (2021) -
Vasculogenic mimicry structures in melanoma support the recruitment of monocytes
por: Tan, Lih Y., et al.
Publicado: (2022) -
Knowing the tumour microenvironment to optimise immunotherapy
por: MERLANO, M.C., et al.
Publicado: (2019) -
Modifying tumor-associated macrophages: An important adjunct to immunotherapy
por: Fridlender, Zvi G, et al.
Publicado: (2013) -
Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome
por: Tan, Lih Yin, et al.
Publicado: (2016)